Xerion Healthcare

Xerion Healthcare has developed nanoparticles specifically to increase the effectiveness of cancer treatments. The particles, which are titanium dioxide-based, are injected into tumours prior to standard radiotherapy and amplify the dose of free radicals generated by the X-rays. Initial targets for the technology are head and neck and pancreatic cancers.